Dr. Abraham is a Clinical Senior Lecturer in Rheumatology and General Internal Medicine. She undertook her medical training in London, Oxford and Cambridge. She was a Clinical Lecturer at the Kennedy Institute of Rheumatology and undertook her PhD, as a Wellcome Clinical Training Fellow, examining the effect of glucocorticoids on pro-inflammatory intracellular signalling. Her novel finding was that a Dual Specificity Phosphatase (DUSP1) renders partial glucocorticoid resistance (J Exp Med 2006).
Research interests and responsibilities
Basic Science interests include intracellular signalling regulation, post-transcriptional regulation and RNA stability.
She is lead for clinical trials in inflammatory arthritis and north-west London CLRN Rheumatology lead. Nationally, she is the CCRN musculoskeletal industry liaison lead.
With her interest in translational and experimental medicine, she is developing a biomarker/imaging and drug discovery programme in Psoriatic arthritis (Psa)and Psoriasis (Pso) with Professor Dorian Haskard. Additionally, she is keen to identify molecular effects of biologics in inflammatory arthritides including Psa, ankylosing spondylitis and rheumatoid arthritis with an aim to understanding the biology of these diseases in relation to phenotype and disease activity.
Education interests and responsibilities
Dr. Abraham has successfully co-supervised MD and clinical PhD students in experimental translational inflammatory arthritis. These students presented their work at international meetings and have been awarded prestigious prizes.
She is the Rheumatology academic clinical fellow (ACF) lead at Imperial and successfully facilitated the creation of the first ACF in London. She is also Lead for Undergraduate Year 5 Rheumatology education at Imperial and an Arthritis Research UK student mentor.
She has been awarded grants from STeLi for “Patient-centric Education” and “Joint examination and injection simulation education”.
Additionally, she is engaged in a number of Public and Patient engagement initiatives to help understanding the needs and value of biomedical research.
Dr. Abraham is committed to nurturing and supporting future academic rheumatologists and training future clinical rheumatologists to help lead/support clinical research.
et al., 2019, Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial, Lancet Infectious Diseases, Vol:19, ISSN:1473-3099, Pages:1091-1100
et al., 2019, Advancing research paradigms and pathophysiological pathways in psoriatic arthritis and ankylosing spondylitis: Proceedings of the 2017 Platform for the Exchange of Expertise and Research (PEER) meeting, Seminars in Arthritis and Rheumatism, Vol:48, ISSN:0049-0172, Pages:1005-1013
et al., 2019, Acute aseptic arthritis: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data, Vaccine, Vol:37, ISSN:0264-410X, Pages:384-391
et al., 2018, Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine, Human Gene Therapy, Vol:29, ISSN:1043-0342, Pages:1011-1028
et al., 2018, The use of biomarkers as a tool for novel psoriatic disease drug discovery, Expert Opinion on Drug Discovery, Vol:13, ISSN:1746-0441, Pages:875-887